Although it can be reasonably assumed that FGFR2 amplification is a negative prognostic indicator in patients with resectable gastric cancer [21–23], these results cannot be applied to metastatic or locally advanced unresectable gastric cancer, as noted in the present and recently published studies [31, 32]. The gene discussed is FGFR2; the disease is gastric cancer.